SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Diginex Ltd. (Hong Kong) is a blockchain financial services and technology company. Its products include diginexESG, diginexLUMEN, diginexAPPRISE, diginexLUMEN Pro, and CSRD framework. The company was founded by Miles Christian Pelham on May 15, 2020 and is headquartered in London, the United Kingdom.

Diginex Ltd.

DGNX is trending due to its recent acquisition of The Remedy Project, sparking discussions about the company's expansion into human-rights remediation. The community is also actively analyzing potential trading strategies based on historical patterns of similar stocks. Options traders are closely monitoring put contracts, anticipating potential downside amidst the volatility.

mF International Ltd. is a holding company, which engages in the development and provision of financial trading solutions through its subsidiary. It offers real-time mission critical forex, bullion and commodities trading platform solutions, financial value-added services, mobile applications, and financial information for brokers and institutional clients via internet or platform as software as a service. The company was founded by Tai Wai Lam and Chi Weng Tam on June 15, 2022, and is headquartered in Hong Kong.

mF International Ltd - Ordinary Shares - Class A

mF International Ltd

mF International ($MFI) is trending due to a recently announced $500M private placement to launch a digital asset treasury strategy, sparking both excitement and skepticism among investors. Some community members speculate about the company becoming a major crypto player, drawing comparisons to MicroStrategy ($MSTR) and highlighting the involvement of figures from the crypto world, while others worry about potential dilution and a pump-and-dump scheme.

Zoom Communications, Inc. engages in the provision of a communications and collaboration platform. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa. The company was founded by Eric S. Yuan in 2011 and is headquartered in San Jose, CA.

Zoom Communications Inc. - Ordinary Shares - Class A

Zoom Video Communications, Inc.

Zoom ($ZM) is trending as investors anticipate the Q3 earnings report and strategic moves, especially in AI, with analysts pointing to potential upside. The community is actively discussing whether Zoom's partnerships with Oracle and NVIDIA will drive enterprise adoption amid modest revenue growth guidance. Mixed sentiment exists, with some traders betting on a post-earnings surge, while others foresee a continued flatlining or even a decline.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending amidst community discussion around its valuation and future prospects in the quantum computing sector. While some express optimism regarding long-term potential and technological advancements, others highlight concerns about revenue, profitability, and insider selling. Community members are actively debating the stock's fair value and potential catalysts.

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

BMY is trending due to discussions around potential acquisitions and strong options activity, with traders highlighting significant profit potential on call options. Community members are speculating about BMY's next strategic move in the pharmaceutical landscape, particularly in areas like oncology and immunology, as well as potential mergers with other companies. Despite some generic competition challenges, the stock is being viewed as a value play with a high dividend yield, especially with discussions around strong revenue growth in Q2.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as community members promote the memecoin and its association with cannabis culture on the Solana blockchain. The coin is being touted as 'like Bitcoin but way higher' with users sharing links to the project's website and social media.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE is trending as its community rallies around the original meme, pushing for widespread adoption and celebrating the return of OG internet culture. The community is actively creating artwork, hosting voice chats, and branching out across social media platforms to build momentum. Many believe $RAGE embodies the raw, real spirit of early internet memes and are committed to its success.

Pony.ai, Inc. develops artificial intelligence-based robot designed for autonomous driving. The firm's software algorithms and infrastructure enables a vehicle to perceive its surroundings, predict what others will do, and maneuver itself accordingly. The company was founded by Jun Peng and Tian Cheng Lou in November 4, 2016 and is headquartered in Guangzhou, China.

Pony AI Inc. - ADR

Pony AI Inc

Pony AI Inc is trending due to the excitement surrounding its expansion and robotaxi initiatives, particularly after securing a permit for driverless robotaxi services in Shanghai. Community discussions revolve around the stock's volatility and potential for growth, with some analysts issuing bullish ratings and price targets. Investors are weighing the company's partnerships, revenue streams, and competition within the autonomous vehicle market.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending as investors debate its valuation and future prospects within the quantum computing sector, especially following a recent pullback. Community discussions revolve around potential catalysts like upcoming presentations and the impact of broader market trends, while some express concern over its high valuation relative to revenue. The acquisition of Skyloom Global and Amazon selling its shares add further fuel to the debate around the company's long-term potential.

Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focusing on the development of its product candidates. It operates through the following geographical segments: Europe, North America, Asia, and Other. The company was founded by Róbert Vilhelm Wessman in 2013 and is headquartered in Luxembourg.

Alvotech

Alvotech ($ALVO) is trending due to recent FDA updates on its biosimilar pipeline, specifically a complete response letter for AVT05 and approval in the European Economic Area for AVT03. The community is actively debating the implications of these regulatory decisions on the company's revenue outlook and potential market share, along with speculation about market manipulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FY2025 Earnings Forecast for DRUG Issued By Chardan Capital

Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) - Equities researchers at Chardan Capital issued their FY2025 earnings estimates for Bright Minds Biosciences in a research report issued on...

Why Bright Minds Biosciences Stock Topped the Market on Monday

Key PointsDays after starting a new investigational program, it announced four appointments to its scientific advisory board...

Bright Minds Biosciences Inc. (DRUG) is on the Move, Here's Why the Trend Could be Sustainable 

Bright Minds Biosciences Inc. (DRUG) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Wall Street Analysts Believe Bright Minds Biosciences Inc. (DRUG) Could Rally 81.29%: Here's is How to Trade

The consensus price target hints at an 81.3% upside potential for Bright Minds Biosciences Inc. (DRUG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Bright Minds Biosciences Inc. (DRUG) Have the Potential to Rally 114.07% as Wall Street Analysts Expect?

The consensus price target hints at an 114.1% upside potential for Bright Minds Biosciences Inc. (DRUG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

What's Going On With Bright Minds Biosciences Stock Friday?

Bright Minds Biosciences shares are moving higher on Friday. The company announced a $35 million non-brokered private placement.
read more...

Shares of nanocap Bright Minds Biosciences, Inc. (<a class="mention" data-mention="$DRUG" data-symbol-id="DRUG" href="https://stocktwits.com/symbol/DRUG" target="_blank">$DRUG</a>) surged 47% in pre-market trading on Friday, making it one of the top five trending tickers on Stocktwits.The spike followed the company’s announcement of a non-brokered private placement of common shares priced at $21.70 per share, Thursday’s closing price, with aggregate gross proceeds expected to reach up to $35 million.Bright Minds intends to allocate these funds toward research and development for its drug development programs, as well as general working capital.Just two days prior, Bright Minds announced promising data from preclinical testing of BMB-201, a non-opioid alternative for neuropathic pain relief, conducted in partnership with the National Institutes of Health’s pain screening program.In nerve ligation pain models, BMB-201 demonstrated efficacy comparable to morphine, exhibiting superior reductions in mechanical allodynia and pain-related behaviors.The company stated that BMB-201 might provide better pain relief than traditional opioid treatments while mitigating the risks of dependency and adverse side effects.With these encouraging preclinical results, Bright Minds plans to advance BMB-201 into clinical trials to further assess its safety and efficacy in human subjects.Additionally, Firefly Neuroscience ($AIFF) had also announced a collaboration with Bright Minds to analyze data from its first-in-human Phase 1 study of its lead compound, BMB-101.Earlier this week, DRUG became an <a href="https://stocktwits.com/news-articles/markets/equity/drug-stock-falls-pre-market-after-1500-percent-surge/cJczTIWR4H">unlikely top gainer</a> across U.S. exchanges, soaring over 1,440% without any apparent catalyst. This prompted the company to issue a statement noting it was “unaware of any material changes in the company’s operations that would account for the recent increase in market activity.”On Stocktwits, the retail following for DRUG has surged 125% over the past week, while message volume has skyrocketed by over 290 times in the past month.Read next: <a href="https://stocktwits.com/news-articles/markets/equity/axp-stock-falls-premarket-after-q3-earnings/cJ22K06RIm">AmEx Stock Dips Pre-Market On Q3 Revenue Miss, But Retail Focuses On Bright Spots</a>

Bright Minds intends to allocate these funds toward research and development for its drug development programs, as well as general working capital.

Bright Minds Biosciences Stock Back In Retail’s Spotlight With $35M Funding Round Via Private Placement

Just two days prior, Bright Minds announced promising data from preclinical testing of BMB-201, a non-opioid alternative for neuropathic pain relief

Equity

Just two days prior, Bright Minds announced promising data from preclinical testing of BMB-201, a non-opioid alternative for neuropathic pain relief


Shares of Bright Minds Biosciences, Inc. ($DRUG) dropped by as much as 34% in pre-market trading on Wednesday after an enormous 1,445% surge in the previous session.Despite the apparent profit-booking, retail interest remains high.The Vancouver-incorporated biotech company issued a press release late Tuesday stating it was “unaware of any material changes in the company’s operations that would account for the recent increase in market activity.”That was reportedly in response to a request from the Canadian Investment Regulatory Organization, which oversees trading on the company’s home exchange.On Stocktwits, DRUG was the top trending ticker early Wednesday, with message volume spiking nearly 2,500% in the previous session. Retail interest surged, with the stock gaining 71% more followers.<stembedurl>https://stocktwits.com/TheRealShortSqueezy/message/588993273</stembedurl><stembedurl>https://stocktwits.com/etrade/message/588956007</stembedurl>Pre-market trading volume as of 7:15 a.m. ET, Wednesday, was at about 600,000 shares, far exceeding the daily average of just 24,000.Bright Minds focuses on developing drugs targeting serotonin-mediated diseases, and recently started a Phase 2 trial for a treatment aimed at drug-resistant epilepsy.The company, which has yet to generate any revenue, in August reported a net loss of $1.8 million for the nine months ending June 30, 2024 — down significantly from a $5.8 million loss during the same period in 2023.With $6.2 million in cash and working capital of $6.1 million, it said it has sufficient funds to operate through 2026.As of Tuesday’s close, Bright Minds’ stock has gained 1,991% year-to-date.The sudden rise sent its market cap soaring from $4 million to nearly $172 million before the pre-market drop.

Bright Minds focuses on developing drugs targeting serotonin-mediated diseases.

Bright Minds Biosciences Stock Falls Pre-Market After Whopping 1,445% Gain, But Retail’s Still Hooked

The biotech company issued a press release late Tuesday stating it was “unaware of any material changes in the company’s operations that would account for the recent increase in market activity.” 

DRUG Stock Sees Profit-Booking Pre-Market After Massive 1,445% Gain, But Retail’s Still Hooked

Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy

Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy Bright Minds Biosciences Initiates the...

Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company was founded by Ian B. McDonald and Alan P. Kozikowski on May 31, 2019 and is headquartered in New York, NY.

Current Price	$58.59
Prev Close	$57.44
Open	$57.32
Dividend Yield	0.00%
50-Day Moving Average	$57.04
Beta	0.90
Avg. Volume	142,330.96
PE Ratio	-61.90

52-Week High	$70.23
52-Week Low	$23.18
Market Capitalization	$456.17M
EPS (Annual)	-$0.4777
Price to Book	10.93
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

DRUG
Bright Minds Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DRUG News

DRUGBright Minds Biosciences Inc